Press Releases October 8, 2026 07:00 AM

Lexeo Therapeutics to Participate in the Chardan Healthcare Conference

Lexeo Therapeutics to Host Fireside Chat at Chardan Healthcare Conference

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
LXEO

Lexeo Therapeutics, a clinical-stage biotech company focused on genetic diseases, announced its participation in the Chardan 10th Annual Healthcare Conference with a fireside chat. The event will be webcast live and is aimed at updating investors and stakeholders on the company's progress and pipeline.

Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
LXEO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Lexeo Therapeutics is advancing a portfolio of therapies targeting genetic cardiovascular and neurological diseases, including candidates for Friedreich ataxia and arrhythmogenic cardiomyopathy.
  • The company will present at a reputable healthcare conference, offering transparency and potential investor engagement.
  • The webcast and subsequent replay provide broader access to the company's development strategy and pipeline progress.

NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at Chardan’s 10th Annual Healthcare Conference on October 20, 2026 at 9:30am ET.

The event will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcast will be available on the Lexeo website following the presentation.

About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.

Media Response:
[email protected]

Investor Response:
Ashley Kaplowitz
[email protected]


Risks

  • As a clinical-stage company, Lexeo's therapies are still in development and face regulatory and clinical trial success risks.
  • Outcomes from the conference presentation may not immediately affect stock price or investor perception significantly.
  • The genetic disease treatment sector is competitive and dependent on scientific breakthroughs, which are uncertain and can impact market acceptance.

More from Press Releases

CNH Names Paul Dick, President, North America Nov 20, 2026 Harmony Biosciences to Participate in Upcoming Investor Conferences Nov 19, 2026 Pure Cycle Announces Record Financial Results For the Year Ended August 31, 2026 Nov 18, 2026 Sachem Capital Reports Third Quarter 2026 Results Nov 16, 2026 Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026